Method for Treating Triple-Negative Breast Cancer Using AMPI-109


Breast cancer is the principle cause of cancer-related mortality in women. Gene profiling has clustered the disease into five major subtypes based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epi- dermal growth factor receptor 2 (HER2). Triple-negative breast cancers (TNBCs) comprise 15– 20% of all newly diagnosed cases and are frequently high grade invasive tumors that lack significant expression of these three markers. Conventional treatments that target those factors are unsuitable. Cytotoxic chemotherapy is frequently utilized as the standard of care for women diagnosed with metastatic TNBC and there are currently no approved targeted agents for these patients.

AMP109 kills cancer cells and has little to no effect on normal cells when compared to common breast cancer chemotherapeutics such as paclitaxel and doxorubicin. A novel therapeutic option with unique mechanisms of action.  AMPI-109 demonstrates synergy as combinatorial agent with chemotherapeutic agents and is potentially beneficial in combination with immune check-point modulators.

For Information, Contact:
Mary Tapolsky
University of Colorado
James Lambert
Hamid Gari
M. Scott Lucia
Rahul Ray
Ann Thor
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum